• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

作者信息

Fay Andre P, Antonarakis Emmanuel S

机构信息

PUCRS School of Medicine, Sao Lucas Hospital at PUCRS, Porto Alegre, Brazil.

Oncoclinicas Institute, Sao Paulo, Brazil.

出版信息

Ann Transl Med. 2019 Mar;7(Suppl 1):S7. doi: 10.21037/atm.2019.01.37.

DOI:10.21037/atm.2019.01.37
PMID:31032288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6462610/
Abstract
摘要

相似文献

1
Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?阻断晚期前列腺癌中的PD-1/PD-L1轴：我们是否在朝着正确的方向前进？
Ann Transl Med. 2019 Mar;7(Suppl 1):S7. doi: 10.21037/atm.2019.01.37.
2
Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling.中药CFF-1通过EGFR/JAK1/STAT3通路抑制PD-1/PD-L1检查点信号，发挥强大的抗肿瘤免疫作用，以阻碍前列腺癌的肿瘤生长和转移。
Phytomedicine. 2022 May;99:153939. doi: 10.1016/j.phymed.2022.153939. Epub 2022 Jan 14.
3
Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.阻断 PD-1/PD-L1 轴可增强骨肉瘤的顺铂化疗的体内外疗效。
Environ Health Prev Med. 2019 Dec 21;24(1):79. doi: 10.1186/s12199-019-0835-3.
4
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer.治疗性阻断 VEGF 与神经纤毛蛋白-2 的结合可降低 PD-L1 表达，激活前列腺癌中的抗肿瘤免疫。
Sci Transl Med. 2023 May 3;15(694):eade5855. doi: 10.1126/scitranslmed.ade5855.
5
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.PD-1/PD-L1通路阻断作为一种有效且实用的癌症免疫治疗方法。
Cancer Biol Med. 2018 May;15(2):116-123. doi: 10.20892/j.issn.2095-3941.2017.0086.
6
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.FDA 对 PD-1/PD-L1 阻断抗体临床试验中转移性非小细胞肺癌老年患者生存情况的分析。
Semin Oncol. 2018 Aug;45(4):220-225. doi: 10.1053/j.seminoncol.2018.08.007. Epub 2018 Oct 31.
7
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
8
The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer.PD-L1/PD-1 轴阻断癌症中的中性粒细胞细胞毒性。
Cells. 2021 Jun 15;10(6):1510. doi: 10.3390/cells10061510.
9
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.ATM/NEMO 信号转导调节多西他赛化疗后前列腺癌细胞程序性死亡配体 1 的表达。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-001758.
10
Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.脂肪细胞通过改变肿瘤细胞中PD-L1/NKG2D配体水平，影响去势抵抗性前列腺癌细胞对NK细胞细胞毒性作用产生抗性。
Prostate. 2018 Apr;78(5):353-364. doi: 10.1002/pros.23479. Epub 2018 Jan 12.

引用本文的文献

1
PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.PD-L1在恶性肿瘤中的重要性：对PD-L1在恶性肿瘤中作用的全面见解，从分子机制到治疗机遇
Clin Exp Med. 2025 Apr 3;25(1):106. doi: 10.1007/s10238-025-01641-y.
2
Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives.前列腺癌的免疫治疗：现状与新的治疗前景。
Curr Oncol. 2023 Jun 13;30(6):5769-5794. doi: 10.3390/curroncol30060432.
3
Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.潜在调控网络的紧急动力学将前列腺癌中的上皮-间质转化与雄激素受体依赖性耐药联系起来。
Comput Struct Biotechnol J. 2023 Feb 8;21:1498-1509. doi: 10.1016/j.csbj.2023.01.031. eCollection 2023.
4
Tumour mutational burden: primary versus metastatic tissue creates systematic bias.肿瘤突变负荷：原发性组织与转移性组织产生系统性偏差。
Immunooncol Technol. 2019 Dec 16;4:8-14. doi: 10.1016/j.iotech.2019.11.003. eCollection 2019 Dec.
5
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, , , and Other Genes.关于前列腺癌中PD-L1表达我们需要了解什么？一项系统文献综述（第6部分）：PD-L1表达与错配修复系统状态及其他基因的相关性
Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
6
Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.免疫检查点抑制剂、ADT 和疫苗联合治疗 mCRPC：数学模型。
PLoS One. 2022 Jan 11;17(1):e0262453. doi: 10.1371/journal.pone.0262453. eCollection 2022.
7
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.BRCA 基因突变与前列腺癌：评估、影响及治疗策略考量。
Int J Mol Sci. 2021 Nov 23;22(23):12628. doi: 10.3390/ijms222312628.
8
Comprehensive analysis of alternative splicing profiling reveals novel events associated with prognosis and the infiltration of immune cells in prostate cancer.对可变剪接谱的综合分析揭示了与前列腺癌预后和免疫细胞浸润相关的新事件。
Transl Androl Urol. 2021 Jul;10(7):3056-3068. doi: 10.21037/tau-21-585.
9
Endoplasmic reticulum oxidoreductase 1 alpha modulates prostate cancer hallmarks.内质网氧化还原酶1α调节前列腺癌的特征。
Transl Androl Urol. 2021 Mar;10(3):1110-1120. doi: 10.21037/tau-20-1025.
10
Using nanoparticles for vaccination against cancer: mechanisms and immunotherapy benefits.利用纳米颗粒进行癌症疫苗接种：机制和免疫疗法的益处。
Int J Hyperthermia. 2020 Dec;37(3):18-33. doi: 10.1080/02656736.2020.1802519.

本文引用的文献

1
Aggressive-Variant Microsatellite-Stable POLE Mutant Prostate Cancer With High Mutation Burden and Durable Response to Immune Checkpoint Inhibitor Therapy.具有高突变负荷且对免疫检查点抑制剂治疗有持久反应的侵袭性变异微卫星稳定POLE突变型前列腺癌
JCO Precis Oncol. 2018 Nov;2:1-8. doi: 10.1200/PO.17.00097.
2
Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.前列腺癌中程序性死亡受体-1 抑制的生物标志物。
Oncologist. 2019 Apr;24(4):444-448. doi: 10.1634/theoncologist.2018-0546. Epub 2018 Dec 12.
3
Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.细胞周期蛋白依赖性激酶12、免疫与前列腺癌
N Engl J Med. 2018 Sep 13;379(11):1087-1089. doi: 10.1056/NEJMcibr1808772.
4
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.伊匹单抗联合纳武单抗与AR-V7表达的转移性前列腺癌中的DNA修复缺陷
Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564.
5
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.CDK12 失活定义了一类独特的免疫原性晚期前列腺癌。
Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034.
6
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展：精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
7
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.前列腺癌原发灶和转移灶中程序性死亡配体 1 表达的综合评估。
Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.
8
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.前列腺癌免疫疗法：我们将何去何从？- 第一部分：前列腺癌疫苗
Oncology (Williston Park). 2018 Mar 15;32(3):112-20.
9
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
10
Comprehensive Analysis of Hypermutation in Human Cancer.人类癌症中高突变的综合分析。
Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.